ORBITA Study: 60 Second Insights
Published: 03 August 2018
-
Views:
1542
-
Likes:
7
-
Views:
1542
-
Likes:
7
-
Up Next -
31sPart 4 | Session 2 Ajay Kirtane
-
52sPart 4 | Session 3 Darrel Francis
-
1m 12sPart 4 | Session 4 Rasha Al-Lamee
-
21sPart 5 | Session 1 Gregg Stone
-
18sPart 5 | Session 2 Ajay Kirtane
-
33sPart 5 | Session 3 Darrel Francis
-
1m 9sPart 5 | Session 4 Rasha Al-Lamee
-
13sPart 6 | Session 1 Gregg Stone
-
39sPart 6 | Session 2 Ajay Kirtane
-
56sPart 6 | Session 3 Darrel Francis
-
1m 11sPart 6 | Session 4 Rasha Al-Lamee
-
1m 11sPart 7 | Session 1 Gregg Stone
-
34sPart 7 | Session 2 Ajay Kirtane
-
1m 6sPart 7 | Session 3 Darrel Francis
-
1m 4sPart 7 | Session 4 Rasha Al-Lamee
-
28sPart 1 | Session 1 Gregg Stone Gregg Stone
-
49sPart 1 | Session 2 Ajay Kirtane Ajay J Kirtane
-
1m 1sPart 1 | Session 3 Darrel Francis Darrel P Francis
-
37sPart 1 | Session 4 Rasha Al-Lamee Rasha Al-Lamee
-
1m 1sPart 2 | Session 1 Gregg Stone Gregg Stone
-
46sPart 2 | Session 2 Ajay Kirtane Ajay J Kirtane
-
1m 8sPart 2 | Session 3 Darrel Francis Darrel P Francis
-
1m 9sPart 2 | Session 4 Rasha Al-Lamee Rasha Al-Lamee
-
31sPart 3 | Session 1 Gregg Stone Gregg Stone
-
43sPart 3 | Session 2 Ajay Kirtane Ajay J Kirtane
-
1m 6sPart 3 | Session 3 Darrel Francis Darrel P Francis
-
1m 16sPart 3 | Session 4 Rasha Al-Lamee Rasha Al-Lamee
Overview
A short series of 60-second insight videos on the ORBITA Study. Hear the expert views in under one minute!
More from this programme
Part 1
Can you describe the ORBITA study in your own words?
Part 2
Why do you think that ORBITA failed to show a significant improvement in exercise capacity post PCI?
Part 3
After the results of ORBITA should we stop stenting?
Part 4
What was the biggest weakness of ORBITA?
Part 5
What is the biggest strength of ORBITA?
Part 6
How has ORBITA affected your clinical practice?
Part 7
Is there a need for further studies?
Faculty Biographies
Gregg Stone
Professor of Medicine, Professor of Population Health Sciences and Policy, and Director of Academic Affairs
Dr Stone is a leading expert in interventional cardiology and is one of the most widely cited researchers in science. He has served as the principal investigator for approximately 130 national and international multicentre randomised trials, has delivered thousands of lectures internationally, and has authored more than 2,500 book chapters, manuscripts and abstracts published in peer-reviewed literature.
Dr Stone is the Director of Academic Affairs for Mount Sinai Heart Health System, and Professor of Medicine and Professor of Population Health Sciences and Policy at The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine, at Mount Sinai, New York.
Dr Gregg Stone is an editorial board member of Interventional Cardiology: Reviews, Research, Resources (ICR3).